
tips for the first meeting with a VC: we will focus primarily on (1) the team, (2) the clinical need, and (3) how solid is the science #quick_notes_LP

Founder & Managing Partner at Invivo Capital - Healthequity, Venture Capital investor in life sciences. PhD, neurosurgeon, Global Executive MBA (IESE). I paint.

tips for the first meeting with a VC: we will focus primarily on (1) the team, (2) the clinical need, and (3) how solid is the science #quick_notes_LP


THE INSIDE STORY OF AN INVESTMENT/ We are proud to announce that our portfolio company ESOBIOTEC is to be acquired by ASTRAZENECA in a landmark early-stage deal totaling $1B ($425M upfront), only 16 months after our investment. Read here: linkedin.com/posts/lluispare…

PORTFOLIO NEWS/ I’m proud to announce the first investment from our new fund, Invivo Ventures III. Neumirna Tx has secured a €20M Series A, led by Invivo Partners and Angelini Ventures (corporate arm of Angelini Pharma), to develop RNA-based therapies for drug-resistant epilepsy

🏥🚀 Vine a les jornades del #CampusClínicInnova 2024 on ponents destacats parlaran sobre innnovació en salut: ✔️ Disseny de sistemes de simulació en salut ✔️ Teràpies avançades ✔️ El futur de la medicina ✔️ IA en transformació digital Inscriu-t'hi 👉 i.mtr.cool/tymggnnbgb

Engaging discussion on challenges, trends, and value drivers shaping the C> space, and the potential growth opportunities in Europe at #ATE24 At @InvivoPartners , we believe the C> field will advance into new indications, novel cell types, and cutting-edge technologies.

Lovely summary by Drs Luis Pareras and Cinta Díez at @InvivoPartners in interesting strategies to bypass T cell dysfunction!!! Just amplifying their ideas/concepts of interest!!!

Sam Altman: “Hire for values first, aptitude second, and skills third.” Most executive recruiters, Sam argues, will reverse this order: “If you say I need to hire a CFO, they will bring you people with 20 years of experience as a CFO at vaguely similar companies. But unfortunately, it’s usually like 20 years of the exact same year of experience over and over again.” But if you’re trying to scale fast, values are most important: “You really need someone who is aligned with the values of the company so that when things change or when they have to make a decision, they’ll make the one you would make if you can’t be there or they will be a good team player and go do that thing.” Sam continues: “You need someone who has high aptitude because the role is going to constantly shift. And the rate of learning - the rate of improvement - dominates skills.” And then skills obviously matter, but for Sam it’s third on the list: “The very best companies take this exceptionally far in how much they’re willing to hire a non-traditionally qualified executive.” Video Source: @ycombinator

PODCAST/ Here’s my conversation with Christian @Soschner where we talk about AI, Synbio, Art, and the Future of Mankind. Below is the original post from Christian with the full video (a little over 2 hours). CLICK HERE TO WATCH THE EPISODE: lnkd.in/e6_74SgK

10. Energy, not compute, will become the primary bottleneck: A gigawatt—akin to running a nuclear plant dedicated solely to training—hasn't been attempted.

9. A New Kind of Science: Unprecedented progress in fields such as quantum mechanics, astronomy, energy, physics, etc., is being driven by AI's application in solving complex scientific problems (would solving the Riemann hypothesis be a valid test of true creative intelligence?)

8. Understanding Emergence: Exploring how consciousness arises from complexity helps explain why AI is so effective at replicating human intelligence.

7. Safety: As we race towards breakthroughs, red teaming and stringent regulatory oversight are essential to navigate the risks, especially in AI and synbio. The race to AGI brings an economic incentive and a prisoner's dilemma scenario

6. Ethics: The field is rife with ethical dilemmas, from how to deal with fake news and societal changes due to employment disruption, to the ethics of dealing with new intelligences with rights.

5. Physical Intelligence & Robotics: Embodied LLMs in robots are poised to be the next major market sensation. This field will explode, much like smartphones did, with potential sales reaching billions as robotics become ubiquitous.

4. Synbio fusion with AI: No synbio company will thrive without AI. Both will enable the creation of new metabolic pathways & designed cells capable of performing functions beyond our imagination.